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Introduction- It is unclear whether a different combination of physical capability markers 
used to define sarcopenia results in a stronger association with health outcomes. Aim: To 
compare the associations between different combinations of physical capability markers of 
sarcopenia with cardiovascular and respiratory outcomes and all-cause mortality. 
Study design- 469,830 UK Biobank participants were included in this prospective study. Four 
groups were derived based on combinations of three physical capability markers used to 
define sarcopenia or severe sarcopenia: gait speed, grip strength and muscle mass. Outcomes 
studied were all-cause mortality, as well as incidence and mortality from cardiovascular 
disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD).  
Results- All combinations of physical capability markers used to define sarcopenia or severe 
sarcopenia identified individuals at increased risk of respiratory disease and all-cause 
mortality. However, the definition most strongly associated with a wide range of adverse 
health outcomes was the combination of slow gait speed plus low muscle mass, followed by 
severe sarcopenia, and the combination of slow gait speed plus low grip strength. The current 
definition of sarcopenia (low grip strength plus low muscle mass) had the weakest 
associations with all-cause (HR: 1.35 [95% CI: 1.07 to 1.71]) and respiratory mortality (HR: 
1.88 [95% CI: 1.15 to 3.10]), as well as respiratory disease (HR:1.38 [95% CI: 1.11 to 1.73]) and 
COPD incidence (HR:2.08 [95% CI: 1.14 to 3.79]).  
Conclusions- Associations of sarcopenia with adverse outcomes were strongest when 
sarcopenia was defined as slow gait speed plus low muscle mass, followed by severe 
sarcopenia, suggesting that this combination of physical capability markers should be still 









Low grip (muscle) strength, low muscle mass and slow walking pace (gait speed) have been 
shown to be strong independent predictors of morbidity and mortality in middle-aged and 
old-aged populations [1-3]. These markers of physical capability are all known to decline after 
the age of ~35 years, and with the rapid growth of ageing populations, the number of 
individuals with low levels of physical capability is also expected to be increased rapidly. This, 
in turn, will increase the number of people who are at higher risk of developing non-
communicable diseases [4]. Although markers of physical capability are generally investigated 
in isolation, combinations of these predictors are used to define conditions, such as 
sarcopenia. In 1989, Irwin Rosenberg was the first to recognise the age-related decline in lean 
body mass and coined the term “sarcopenia” (from the Greek ‘sarx’ for flesh + ‘penia’ for loss) 
[5, 6]. Nowadays, sarcopenia is defined as a complex syndrome characterised by a progressive 
loss of muscle strength along with a higher risk of disability and reduction in quality of life [7] 
and it is one of the 150 musculoskeletal conditions that contribute to disability worldwide [8]. 
Furthermore, the International Classification of Disease (ICD-10) has recognised sarcopenia 
as an independent condition since September 2016 [9]. 
Although sarcopenia has been clinically recognised as a frailty marker, a global consensus on 
an operational definition has not been reached. This could explain the wide variation in 
reported sarcopenia prevalence, ranging from 3% to 30% for older adults aged 60 years or 
older [10]. In the last ten years, there have been several attempts to standardise the 
operational definition and cut-off points for sarcopenia, most of which have used 
combinations of measures of muscle mass, muscle strength and gait speed [11-13]. The most 




(EWGSOP2), has proposed that sarcopenia should be defined as low muscle strength plus low 
muscle mass, with severe sarcopenia including the addition of slow gait speed [7].  
Although the associations between sarcopenia and all-cause mortality, chronic obstructive 
pulmonary disease (COPD) [14, 15], and cardiovascular diseases (CVD)[16, 17] have been 
previously studied, it is unclear whether a different combination of physical capability 
markers results in a stronger association with health outcomes. The aim of this study, 
therefore, was to compare the association of different combinations of physical capability 
markers used to define sarcopenia with cardiovascular and respiratory outcomes as well as 
all-cause mortality in UK Biobank, a large prospective cohort study of middle-aged adults.  
2. Methods 
Between April 2007 and December 2010, UK Biobank recruited over 500,000 participants 
(5.5% response rate), aged 37-73 years from the general population [18]. Participants 
attended one of 22 assessment centres across England, Wales and Scotland [19, 20] where 
they completed a touch-screen questionnaire, had physical measurements taken, and 
provided biological samples, as described in detail elsewhere [19, 20]. 
The outcomes in the current study were all-cause mortality and incidence and mortality for 
CVD and respiratory diseases, and the exposures were different combinations of physical 
capability markers used to define sarcopenia. Due to ethnic differences in the reference 








Date of death was obtained from death certificates held by the National Health Service (NHS) 
Information Centre (England and Wales) and the NHS Central Register Scotland (Scotland). 
Dates and causes of hospital admissions were identified via record linkage to Health Episode 
Statistics (HES) (England and Wales) and the Scottish Morbidity Records (SMR01) (Scotland). 
Details of the linkage procedure can be found at http://www.ic.nhs.uk/services/medical-
research-information-service. Follow-up data started in March 2008 and were available until 
31 January 2018 for participants in England or Wales, and 30 May 2017 for participants in 
Scotland. Follow-up was censored on these for deaths.  
Incident CVD was defined as a hospital admission or death with ICD10 (International 
Classification of Diseases, 10th revision) codes I60, I61, I63, I64, I21, I21.4, and I21.9. 
Respiratory disease was defined as ICD10 codes J09-J98, and COPD was defined as ICD10 code 
J44.  
2.2 Physical capability markers groups 
The 2019 EWGSOP2 statements define sarcopenia as the combination of low grip strength 
plus low muscle mass and severe sarcopenia as both in combination with slow gait speed [7]. 
To compare the association of different combinations of physical capability markers used to 
define sarcopenia with the health outcomes of interest, we derived four groups, two of which 
were the current EWGSOP2 definition of sarcopenia and severe sarcopenia and the other two 
being the remaining combinations of physical capability markers (Supplementary Figure 1). 
The four groups were therefore as follows: a) slow gait speed plus low grip strength only (gait-
grip group), b) slow gait speed plus low muscle mass only (gait-muscle group), c) low grip 




d) low grip strength plus low muscle mass plus slow walking speed (severe sarcopenia). The 
four groups were mutually exclusive. 
Details about measures and the cut-off points for each physical capability marker as well as 
other sociodemographic, lifestyle and health measures are available in supplementary 
methods.  
2.3 Statistical analyses 
Associations of the combination of physical capability markers with cause-specific incidence 
and mortality were investigated using Cox-proportional hazard models (individuals with a 
normal range for all physical capability markers were used as the reference group). 
Associations between individual physical capability markers and cause-specific incidence and 
mortality are also reported. The results are reported as hazard ratios (HR) and their 95% 
confidence intervals. The proportional hazard assumption was checked by tests based on 
Schoenfeld residuals. All analyses were performed using a 2-year landmark analysis. The 
models for CVD and respiratory incidence and mortality were performed excluding 
participants with medical diagnoses of CVD, or respiratory disease, respectively.  
We produced three models that included an increasing number of covariates: “model 1” 
(minimally adjusted) included sociodemographic covariates (age, sex and deprivation); 
“model 2” (maximally adjusted) was adjusted as in model 1, but also included prevalent 
diseases (hypertension, diabetes, depression, major illness, cancer, as well as CVD and 
respiratory disease when these were not the outcome) and lifestyle factors (smoking, sleep 
duration, waist circumference [WC], total physical activity, total discretionary sedentary time 




meat intake). Sensitivity analyses, where all 71,778 participants with comorbidities at baseline 
(such as CVD, cancer, COPD, diabetes and depression) were excluded from the analyses 
irrespective of the outcome, were conducted to evaluate the association between 
combinations of physical capability markers and health outcomes among apparently 
“healthy” individuals (model 3).  
To investigate whether the association between combinations of physical capability markers 
used to define sarcopenia and health outcomes differed by age and sex, we fitted a 
multiplicative interaction term between sarcopenia and these sociodemographic variables. 
Where these were statistically significant, subgroup analyses were performed, stratified by 
age category (below and above 60 years) and sex as appropriate. 
All analyses were performed using STATA 16 statistical software (StataCorp LP). P-values 
below 0.05 were regarded as statistically significant. 
3. Results 
Of the 502,535 participants recruited to UK Biobank, 469,830 (93.5%) had full data available 
on exposure, outcomes and covariates. The mean follow-up period was 6.9 years 
(interquartile range: 6.3–7.5) after the landmark period for all-cause and cause-specific 
mortality, and 6.0 years (interquartile range: 5.4–6.7) for cardiovascular and respiratory 
disease incidence. Over the follow-up period, 14,786 (3.1%) participants died; 2,548 (0.5%) 
from CVD and 2,577 (0.5%) from respiratory diseases. Additionally, 19,332 (4.1%) participants 
developed cardiovascular disease, 16,105 (3.4%) respiratory disease, and 1,605 (0.3%) COPD. 
The specific numbers of deaths/events for each physical capability marker and their 




The study population’s characteristics by the four physical capability markers groups are 
summarised in Table 1. Overall, in comparison to people without any form of sarcopenia, 
people with any combination of physical capability markers were older, more deprived and 
more likely to be female. For all groups, other than the grip-muscle group (current sarcopenia 
definition), participants were more likely to be current smokers and were less physically 
active. Those defined by low grip strength plus low muscle mass had the lowest body weight, 
and WC and those defined by slow gait speed plus low grip strength had the highest 
prevalence of obesity, central obesity, diabetes, CVD and hypertension. However, people with 
severe sarcopenia had the highest prevalence of fractures and falls in the last 5-years and 1-
year, respectively. The main characteristics of the population by individual physical capability 
markers (gait speed or grip strength or muscle mass) are presented in Supplementary Table 
2. 
The associations between the individual physical capability markers used to define sarcopenia 
and health outcomes are presented in Figure 1 and Supplementary Table 3. These results 
show that slow gait speed had the strongest associations with health outcomes. Low grip 
strength and low muscle mass were associated with similar risk estimate for outcomes except 
for COPD, whereas individuals with low muscle mass had similar risks to those observed for 
slow gait speed. 
As shown in Figure 2, severe sarcopenia had the strongest association with all-cause mortality 
(HR: 3.02 [95% CI: 2.34 to 3.91]), whilst the combination of slow gait speed plus low muscle 
mass (gait-muscle group) showed the strongest association with CVD (HR: 3.47 [95% CI: 2.03 
to 5.91]), and respiratory mortality (HR: 5.73 [95% CI: 3.83 to 8.57]). Severe sarcopenia and 




respiratory mortality, but the magnitude of these associations were lower in comparison to 
the gait-muscle group (Figure 2). However, the combination of low grip strength plus low 
muscle mass, i.e. the current sarcopenia definition, had the lowest magnitude of associations 
compared to other combinations of physical capability markers. Individuals with low grip plus 
low muscle mass had a 35% and 88% higher risk of all-cause and respiratory diseases mortality 
compared to the reference group. No associations were observed between this group and 
CVD mortality. 
All combinations of physical capability markers were associated with a higher incidence risk 
of respiratory diseases (Figure 3), with the strongest association observed for those classified 
as severely sarcopenic (HR: 2.74 [95% CI: 2.06 to 3.65]). In terms of COPD incidence, the gait-
muscle group had 4.16 times higher risk than people with normal physical capability markers 
(HR: 4.16 [95% CI 2.59 to 6.70]), followed by those with severe sarcopenia (HR: 3.85 [95% CI: 
2.24 to 6.62]) and the gait-grip group (HR: 2.42 [95% CI: 2.01 to 2.91]). A lower magnitude of 
association was found for CVD incidence in the gait-muscle group (HR: 1.62 [95% CI: 1.20 to 
2.17]), followed by the gait-grip group (HR: 1.38 [95% CI: 1.27 to 1.50]). However, no 
associations with CVD were found for the severe sarcopenia group and the grip-muscle group. 
When participants with major comorbidities at baseline were excluded from the analyses, the 
magnitude of the associations with all health outcomes increased for the gait-muscle group 
and the gait-grip group. 
There were significant interactions between age and the gait-grip group for all-cause 
mortality, and respiratory mortality and incidence, and between age and severe sarcopenia 
in relation to CVD incidence. In these cases, the magnitude of the associations was slightly 




Interactions were also observed in relation to sex (Supplementary Table 7). Associations for 
all-cause mortality and respiratory incidence with all physical capability groups were stronger 
in men than women. However, women had stronger associations with CVD mortality for all 





Sarcopenia is a progressive, complex disorder associated with the development of a number 
of diseases and contributes to frailty, disability, morbidity and mortality. As detailed 
previously, there are many diagnostic criteria used to define sarcopenia [11-13]. In this study, 
we used the three physical capability markers (gait speed, grip strength and muscle mass) 
used in EWGSOP2 to derive four different combinations of physical capability markers, 
including the current definition of sarcopenia and severe sarcopenia [7]. 
The main finding of this study was that all combinations of physical capability markers used 
to define sarcopenia or severe sarcopenia identified individuals at increased risk of respiratory 
disease and all-cause mortality. However, the definition most strongly associated with a wide 
range of adverse health outcomes was the combination of slow gait speed plus low muscle 
mass, followed by severe sarcopenia, and the combination of slow gait speed plus low grip 
strength. Individuals with these characteristics were at significantly higher risk of developing 
CVD, respiratory disease and COPD incidence as well as all-cause, CVD and respiratory 
mortality. Nevertheless, the new EWGSOP2 guidelines proposed that low muscle strength (or 
grip strength) plus low muscle mass should be used to diagnose sarcopenia [7]. 
 
Whilst the loss of muscle mass was the first and is the most widely recognised characteristic 
of sarcopenia, strength and gait may be better measures of sarcopenia severity and its risk to 
health. In fact, Bachettini el al. showed that gait speed was the only criterion independently 
associated with mortality in the definition of sarcopenia using the EWGSOP2 definition (76% 
higher risk of mortality) [21] and Ganna & Ingelsson demonstrated that the self-reported 




in both men and women [22]. Therefore, a definition, and diagnosis, based on slow gait speed 
and/or low grip strength may be more meaningful for use in clinical practice and research 
since both are quick tests for the sarcopenia diagnosis. In particular, slow gait speed and low 
grip strength appeared to be the main drivers of the observed associations with health 
outcomes more than low muscle mass. In fact, Sim et al. demonstrated that different 
definitions of sarcopenia were not associated with falls-related hospitalisations in older 
Australian women; however, when each physical capability marker was examined 
individually, both grip strength and physical function, but not muscle mass, were associated 
with falls-related hospitalisation [23]. Comparable results were observed for mortality in the 
same cohort [24]. However, despite its potential as a diagnostic tool, grip strength may not 
respond to treatment well, and its use in the continual monitoring of sarcopenic patients can 
be limited [25]. 
In terms of muscle mass, we should note that other measurements on muscle mass could 
provide a better prognostic value. For instance, Cawthon et al. highlighted that when muscle 
mass was determined by creatine concentration, people in the lowest quartile of muscle mass 
had a higher risk of mortality for all-cause, cancer and CVD [26]. However, this method is still 
not recognised as a measurement of muscle mass by the EWGSOP2 [7]. 
In our study, the current definition of sarcopenia and severe sarcopenia were both more 
prevalent in women; however, were associated with a stronger risk of adverse health 
outcomes in men. Women experience an earlier loss of muscle mass and a major decline in 
sex-specific hormones that are important for the muscle maintenance, and therefore they 
could be more susceptible to experiencing sarcopenia early in life; however, men have a 




accompanied by a significant decrease in muscle strength which is intensified when there is 
poor nutrition (e.g. low intake of protein) and lower levels of physical activity [27]. 
Sarcopenia was initially considered a disease of ageing but is now understood to begin before 
older ages [7]. In our study, we demonstrated that the associations were slightly stronger in 
participants aged < 60 years. Our findings, therefore, reinforce the need for earlier detection 
of sarcopenia and altered physical capability markers in clinical practice. 
In terms of health outcomes, other studies have identified similar associations between 
different combinations of physical capability markers used to define sarcopenia and health 
outcomes [14-17]. Zhang et al. showed that sarcopenia was associated with an increased risk 
for all-cause mortality among older nursing home residents (HR: 1.86 [95% CI: 1.42 to 2.45]) 
[28]. By contrast, Kittiskulnam et al. determined that neither sarcopenia nor low muscle mass 
were a good predictor of mortality among patients on haemodialysis; however, when gait 
speed or grip strength were used, a positive association was identified [29]. These findings 
are similar to our study because, although we found a positive association with a different 
classification of sarcopenia, low grip strength and slow gait speed, no associations between 
low muscle mass (the previously more important criterion) and the outcomes were identified. 
Finally, the majority of the strongest associations were with respiratory outcomes. It has been 
postulated that both ageing and sarcopenia may be associated with reduced power of the 
diaphragm muscle, which, in turn, impairs expulsive airway clearance [30]. Jones et al., after 
studying 622 stable patients with COPD, determined that sarcopenia, defined by EWGSOP 
criteria, has an impact on the functional and health status in these patients, specifically those 





Strengths and limitations  
UK Biobank is not representative of the UK population in terms of lifestyle and prevalent 
disease [31]. Therefore, whilst estimates of effect sizes can be generalised, summary statistics 
should not be.  However, the use of UK Biobank allowed us to test our research question in a 
very large general population cohort as well as the opportunity to work with information 
collected using validated and standardised methods. On the other hand, dual-energy X-ray 
absorptiometry (DXA) is the most commonly used method for deriving muscle mass because 
it can provide a reproducible estimation of the appendicular skeletal muscle mass in a few 
minutes. In the UK Biobank study, muscle mass was measured using bioimpedance, but this 
method has been shown to correlate well with DXA (r=0.868, p<0.0001). Finally, walking pace 
was self-reported. Whilst this is potentially a source of bias, it is more easily replicated in 
clinical practice. Future studies are needed to establish whether it is a reasonable proxy of 
objectively measured walking speed. 
In conclusion, even though different combinations of physical capability markers were 
associated with CVD, respiratory, COPD incidence and all-cause, CVD and respiratory 
mortality, there were differences in the strength of association. Notably, the EWGSOP2 
definition was not significantly associated with both fatal and nonfatal CVD. The strongest 
associations were observed for the combination of slow gait speed plus low muscle mass. 
These findings suggest that slow gait speed, which was omitted in defining sarcopenia in the 
current EWGSOP2, may be an important physical capability marker of sarcopenia and its use 
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Socio-demographics      
Total n 394,583 8,731 564 1,678 424 
Sex (Female), n (%) 207,782 (52.7) 5,378 (61.6) 505 (89.5) 1,604 (95.6) 386 (91.0) 
Age (years), mean (SD) 56.1 (8.1) 60.2 (6.8) 62.0 (5.9) 63.0 (5.3) 62.0 (6.3) 
Age categories  
<56 years 































































993 (59.5)        






Obesity-related markers      
Height (metres), mean (SD) 1.69 (0.09) 1.64 (0.09) 1.63 (0.08) 1.61 (0.07) 1.62 (0.08) 
Body weight (kg), mean (SD) 78.0 (15.2) 83.8 (18.6) 62.4 (11.0) 59.6 (8.3) 61.3 (10.3) 
BMI, mean (SD) 27.1 (4.4) 31.2 (6.4) 23.6 (4.0) 22.9 (2.9) 23.5 (3.5) 
BMI Categories, n (%) 
Underweight (<18.5 kg.m-2) 
Normal weight (18.5-24.9 
kg.m-2) 
Overweight (25.0 to 29.9 
kg.m-2) 

















102 (6.1)         
1,171 (69.8)        







Waist Circumference (cm) 89.7 (12.9) 99.2 (15.2) 81.7 (10.6) 78.2 (8.8) 81.4 (10.2) 
Central Obesity, n (%) 121,990 (31.0) 5,638 (64.7) 120 (21.3) 224 (13.4) 99 (23.4) 
% Body fat, mean (SD) 30.7 (8.3) 37.2 (9.0) 37.0 (8.1)  36.1 (6.4) 36.9 (7.5) 
Fitness and Physical activity      












Cardiorespiratory fitness (MET), 
mean (SD) 
9.8 (2.8) 8.0 (2.5) 7.2 (1.7) 7.6 (1.8) 7.6 (1.4) 
Grip Strength (kg), mean (SD) 32.5 (10.3) 14.5 (6.2) 22.2 (5.8) 12.7 (3.7) 10.9 (5.0) 
TV viewing (h.day-1), mean 
(SD) 
2.7 (1.5) 4.0 (2.2) 3.8 (2.0) 3.2 (1.7) 4.0 (2.1) 
Total Sedentary behaviour 
(h.day-1) , mean (SD) 
5.0 (2.2) 5.6 (2.8) 5.3 (2.5) 4.6 (2.0) 5.2 (2.4) 
Health status, n (%)      
Diabetes  15,062 (3.8) 1,470 (17.0) 15 (2.7) 28 (1.7) 14 (3.3) 
CVDs  106,513 (27.0) 5,022 (57.8) 232 (41.3) 443 (26.5) 176 (41.6) 
















Falls, n (%) 
No falls 
Only one fall 





















Gait-grip group: slow gait speed plus low grip strength only. Gait-muscle group: slow gait 
speed plus low muscle mass only. Grip-muscle group or current sarcopenia definition*: low 
grip strength plus low muscle mass only. Severe sarcopenia: having low grip strength plus 
low muscle mass plus slow walking speed. BMI: body mass index; n: number; PA: physical 





Figure Legends  
Figure 1. Association of physical capability markers with incidence and mortality  
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95% CI) by different combinations of physical 
capability markers. People with a normal range for all physical capability markers were used as the reference group for the 
analyses. 
All analyses were conducted using a 2-year landmark analyses and for Model 2, were adjusted for age, sex, deprivation, 
smoking status, sleep duration, WC, total physical activity, discretionary sedentary time, dietary intake (alcohol, fruit and 
vegetable, oily fish, red meat and processed meat intake), hypertension, diabetes, depression, comorbidities, cancer,  as well 
as CVD and respiratory disease when these were not the outcome. 
Figure 2. Association between different combinations of physical capability markers and 
all- and cause-specific mortality 
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95% CI) by different combinations of physical 
capability markers.  
People with a normal range for all physical capability markers were used as the reference group for the analyses. 
 Gait-grip group: having slow gait speed plus low grip strength only. Gait-muscle group: having slow gait speed plus low 
muscle mass only. Grip-muscle group or current sarcopenia definition: having low grip strength plus low muscle mass only. 
Severe sarcopenia: having low grip strength plus low muscle mass plus slow walking speed.  
All analyses were conducted using a 2-year landmark analyses and for Model 2 were adjusted for age, sex, deprivation, 
smoking status, sleep duration, WC, total physical activity, discretionary sedentary time, dietary intake (alcohol, fruit and 
vegetable, oily fish, red meat and processed meat intake), hypertension, diabetes, depression, comorbidities, cancer,  as well 
as CVD and respiratory disease when these were not the outcome. 
 
Figure 3. Association between different combinations of physical capability markers and 
cause-specific incidence 
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95% CI) by different combinations of physical 
capability markers. People with a normal range for all physical capability markers were used as the reference group for the 
analyses. 
. Gait-grip group: having slow gait speed plus low grip strength only. Gait-muscle group: having slow gait speed plus low 
muscle mass only. Grip-muscle group or current sarcopenia definition: having low grip strength plus low muscle mass only. 
Severe sarcopenia: having low grip strength plus low muscle mass plus slow walking speed.  
All analyses were conducted using a 2-year landmark analyses and for Model 2 were adjusted for age, sex, deprivation, 
smoking status, sleep duration, WC, total physical activity, discretionary sedentary time, dietary intake (alcohol, fruit and 
vegetable, oily fish, red meat and processed meat intake), hypertension, diabetes, depression, comorbidities, cancer,  as well 
as CVD and respiratory disease when these were not the outcome. 
 
 
 
